Bioactivation of 5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: A novel co-substrate-mediated antitumor prodrug therapy

Cancer Research

Volumn 60, Issue 15, 2000, Pages 4179-4186

  Knox, R J ^a   Jenkins, T C ^a   Hobbs, S M ^a   Chen, S ^a   Melton, R G ^a   Burke, P J ^a  

^a Enact Pharma PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; NICOTINAMIDE DERIVATIVE; NICOTINAMIDE RIBOSIDE; PRODRUG; PYRIDINIUM DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG ACTIVATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; CELL LINE; CRICETINAE; CRICETULUS; DRUG SCREENING ASSAYS, ANTITUMOR; FIBROBLASTS; HUMANS; ISOENZYMES; NAD(P)H DEHYDROGENASE (QUINONE); NIACINAMIDE; PRODRUGS; PYRIDINIUM COMPOUNDS; SUBSTRATE SPECIFICITY; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033871181     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)
2. DT-diaphorase and cancer chemotherapy
3. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)
4. Phthalimide analogues of CB 1954: Synthesis and bioactivation
5. Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse
6. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954
7. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy
8. The bystander effect of the nitroreductase CB 1954 enzyme prodrug system is due to a cell-permeable metabolite
9. Sensitization of colorectal and pancreatic cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by retroviral transduction and expression of the E. coli nitroreductase gene
10. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954
11. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). I. Purification and properties of a nitroreductase enzyme from Escherichia coli: A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)
12. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase
13. Enzyme-Prodrug Strategies for Cancer Therapy
14. Catalytic properties of NAD(P)H-quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase
15. Nucleotide and deduced amino acid sequence of a human cDNA (NQO-2) corresponding to a second member of the NAD(P)H: Quinone oxidoreductase gene family. Extensive polymorphism at the NQO-2 gene locus on chromosome 6
16. Human NAD(P)H. Quinone oxidoreductase 2. Gene structure, activity, and tissue-specific expression
17. Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide
18. Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide
19. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H: Quinone reductase (DT-diaphorase)
20. Catalytic properties of NAD(P)H: Quinone acceptor oxidoreductase: Study involving mouse, rat, human, and mouse-rat chimeric enzymes
21. Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)
22. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256
23. The pyridinium-dihydropyridine system. I. Synthesis of a series of substituted pyridinium ions and their 1,4-dihydro reduction products and a determination of their stabilities in aqueous buffers
24. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs
25. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1a promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins
26. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)
27. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells
28. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy
29. Gene-directed enzyme prodrug therapy: Quantitative bystander cytotoxicity and DNA damage induced by CB 1954 in cells expressing bacterial nitroreductase
30. Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumor cells by stimulation of DT diaphorase activity
31. Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system
32. Cytosolic NAD(P)H (quinone-acceptor)oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol
33. NAD(P)H. Quinone oxidoreductase-1 (DT-diaphorase) expression in normal and tumor tissues
34. Nicotinamide adenine dinucleotide (phosphate): Quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines
35. Use of quinones in brain-tumor therapy: Preliminary results of preclinical laboratory investigations
36. Increased activity and expression of NAD(P)H: Quinone acceptor oxidoreductase in confluent cell cultures and within multicellular spheroids
37. NAD(P)H: Quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells
38. High levels of expression of the NAD(P)H: Quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin
39. NAD(P)H quinone oxidoreductase 1 (DT-diaphorase): Expression, regulation, and role in cancer
40. Biochemical and quantitative histochemical study of reduced pyridine nucleotide dehydrogenation by human colonic carcinomas
41. Crystal structure of human quinone reductase type 2, a metalloflavoprotein